Heidi
598 employees on LinkedIn Β· 15 known investors
Find your way into Heidi
753 people in our graph share verified history with the Heidi team β schools, employers, funds. One of them is your warm intro.
Heidi builds an AI Care Partner platform that augments clinical workflows through an AI scribe and a medical research tool called Evidence, serving clinicians across hospitals and healthcare systems globally. The platform supports millions of weekly consultations across 110 languages and 190 countries.
Also known as Heidi Health
Founders & leadership
Investors Β· 15
Also in the syndicate Β· 6
Valuation Β· disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed β follow each entry's link for the claim.
Company profile
researched Aug 2026Heidi (Heidi Health) is a healthcare AI company founded in Melbourne, Australia that builds what it calls an "AI Care Partner" for clinicians. Its core product is an ambient AI scribe that captures consultations and produces clinical notes, summaries, codes and follow-up communications; the scribe operates in the background, does not store session recordings, and is designed to work in noisy settings such as emergency departments and surgical theatres as well as primary care. Around the scribe, Heidi has added Evidence, a clinical evidence and guideline search tool; Dictate, a dictation feature that writes into whichever field the user's cursor sits in; and a clip-on remote microphone for capturing notes during ward rounds.
The platform is positioned for enterprise deployment across a broader set of clinical and administrative workflows, including pre-charting and visit preparation, coding and clinical documentation improvement, care-gap identification and outreach, guideline adherence monitoring, patient communications, referral triage, repeat prescription processing, chronic-care remote patient monitoring outreach and revenue leakage identification. Heidi states it complies with NHS requirements, HIPAA, GDPR and the Australian Privacy Principles and holds SOC 2 and ISO 27001 certifications.
As of October 2025 the company reported supporting more than two million consults each week in 110 languages across 116 countries, with 73 million consults supported over the preceding 18 months; its own site later reported roughly 2.7 million patient visits in a week and, on its careers page, about 500 employees and 47 million hours saved since launch.
Founding story
Heidi was founded in Melbourne by Dr Thomas Kelly, a former vascular surgical resident, who has said he started the company to free doctors from non-clinical work after seeing administrative workload drive clinician burnout and attrition.
Business model
Heidi offers a free entry point for individual clinicians ("Get Heidi free") alongside a demo-led enterprise motion aimed at clinics, hospitals and health systems, with an enterprise product covering documentation, coding and broader administrative workflows.
Software offered to individual clinicians with a free tier and to healthcare organisations through enterprise agreements arranged via sales/demo channels.
Traction
Heidi's scribe launched in February 2024 and had supported over 20 million patient interactions by March 2025, when clinicians were using it in more than one million consults a week. By October 2025 the company reported 73 million consults over 18 months, more than two million weekly consults, tens of thousands of clinicians across over 200 specialties, and 18 million clinician hours returned. Named users and deployments include Modality Partnership and Cambridge University Hospitals NHS Foundation Trust in the UK, pilots with NHS trusts in North West London and Lancashire and South Cumbria, Beth Israel Lahey Health and MaineGeneral in the US, ForHealth and Monash Health and Queensland Health's Children's Hospital and Health Service in Australia, Tamaki Health in New Zealand, and the Yukon Government in Canada. New Zealand's Health Ministry endorsed Heidi as one of two healthcare AI providers safe to trial in the public health system.
Latest developments
Recent activity includes the launch of the Dictate feature, a partnership with OneCare Vermont covering primary care practices in Vermont, and an integration with QHR Technologies to embed AI documentation into the Accuro EMR for Canadian clinicians. The company continues to hire broadly across engineering, clinical and customer roles in Australia, the UK, Ireland, the US, Japan and remote locations.
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
Heidi competes in the ambient AI scribe and clinical documentation market alongside vendors such as Suki and Commure. At its Series B it was valued at $465 million with nearly $100 million raised, and reported deployments in the UK, US, Canada, Australia and New Zealand.
According to its investors and its own materials, Heidi differentiates through heavy note customisation rather than deep EMR integration, a global-first go-to-market from Australia, support for 110 languages, and the ability to operate in noisy clinical environments rather than only quiet primary-care rooms.
Technology
Heidi uses its own AI models built on top of Google's Gemini. The scribe runs ambiently, generating notes and downstream documents without storing session recordings; the platform also includes an evidence retrieval capability and dictation, with engineering roles spanning AI models, LLMOps, localisation and cloud reliability on Azure and GCP.
Go-to-market
Heidi combines a product-led, clinician-led adoption motion β a free self-serve product taken up by individual clinicians β with enterprise sales to health systems and partnerships with distributors and EMR vendors such as Hendrix Health in New Zealand and QHR Technologies (Accuro EMR) in Canada. Investors have described the approach as prioritising customisation over complex integrations with a global-first strategy.
Individual clinicians across more than 200 medical specialties, general practices and GP partnerships, specialist clinics, emergency departments, hospitals and public health systems.
Geography
Founded and headquartered in Melbourne, Australia, with eight offices across Australia, the US, UK, Canada and Singapore β Melbourne, Sydney, Brisbane, New York, San Francisco, London, Toronto and Singapore β and hiring in Ireland and Japan. Commercial activity spans the US, UK, Canada, Australia and New Zealand, with growing clinician adoption in France, Spain, Germany, Ireland, South Africa, Singapore and Hong Kong.
History
Heidi raised an A$10 million (about $6.5 million) Series A led by Blackbird Ventures in 2023 and launched its AI scribe in February 2024. In March 2025 it raised a $16.6 million Series A follow-on led by Headline to extend beyond scribing into pre-chart summaries, clinical guidelines and patient engagement, and partnered with Hendrix Health for New Zealand. In October 2025 it closed a $65 million Series B led by Point72 Private Investments at a $465 million valuation, appointing Paul Williamson (ex-Plaid) as Chief Revenue Officer and Dr Simon Kos (ex-Microsoft) as Chief Medical Officer, and set out plans to expand headcount and offices in the US, UK and Canada.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Competitors Β· 5
by search overlap
Companies competing with Heidi for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline Β· 11
launches, deals, and filingsHeidi and QHR Technologies integrated AI documentation into the Accuro EMR for Canadian clinicians.
Heidi launched Dictate, a voice dictation feature that works wherever the user's cursor is placed.
Following the Series B, Heidi said it would expand headcount, office locations and local support in the USA, UK and Canadian markets, and build on clinician-led adoption in France, Spain, Germany, Ireland, South Africa, Singapore and Hong Kong.
Heidi announced a $65 million Series B led by Point72 Private Investments with participation from Blackbird, Headline and Latitude, the growth fund of Phoenix Court, valuing the company at $465 million and bringing total funding to nearly $100 million.
$65M source β
Dr Simon Kos, previously Chief Medical Officer of Microsoft, joined Heidi as Chief Medical Officer.
Paul Williamson, previously Head of Revenue at Plaid, joined Heidi as Chief Revenue Officer.
Heidi announced a partnership with OneCare Vermont to reduce administrative burden for primary care practices across Vermont.
Series A follow-on investment led by Headline with participation from LocalGlobe, Anthology (Menlo Ventures and Anthropic), Blackbird, HESTA, Possible Ventures and Archangel Ventures, to expand capabilities beyond scribing.
$16.6M source β
Heidi partnered with healthcare distributor Hendrix Health to adapt its AI medical scribe to the requirements of New Zealand clinicians.
Heidi was selected by Modality Partnership, the NHS's largest GP super-partnership, in what the company describes as the UK's largest deployment of ambient AI in a clinical setting.
Heidi's AI scribe launched in February 2024; by March 2025 it had supported over 20 million patient interactions globally.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
βΈResearch sources Β· 8
primary sources listed
- Heidiheidihealth.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Heidi do?
- Heidi is an Australian healthcare AI company whose AI Care Partner platform automates clinical documentation and admin tasks.
- Who founded Heidi?
- Heidi was founded by Dr. Thomas Kelly MD, Waleed Mussa.
- Who are Heidi's investors?
- Heidi's investors include Headline, Latitude, Archangel Ventures, Blackbird Ventures, Headline Growth Management, LLC, Menlo Ventures, Point72 Ventures, SNΓ Ventures and 1 more.